Friday, 1 February 2019, 07:00 HKT/SGT
Canbiola Launches Revolutionary CBD Wellness Solution for Tissue Healing and Chronic Pain
- Expected to Accelerate Revenue Growth in 2019 - Commits to1,650 SAM Units in 2019 with Each Potentially Generating
$14,210 Revenue Per Year
Hicksville, NY, Feb 1, 2019 - (ACN Newswire) - via NewMediaWire -- Canbiola, Inc. (OTCQB: CANB) ("Canbiola"), a
developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers,
chews, isolate, gel caps, concentrate and water, announced today the launch and availability of a revolutionary
Sustained Acoustic Medicine ("SAM") wellness solution. SAM, along with its proprietary CBD Gel Capture Patches, is
proven in accelerating tissue healing and chronic pain reduction and is reimbursable by health insurance companies.
The SAM Pro 2.0 is the first and only FDA cleared wearable low-intensity ultrasound device delivering multi-hour
treatment to accelerate healing and improve function for musculoskeletal injuries (muscle, tendon, ligament) and
reducing chronic pain (without opioid pain medication).
Canbiola and its Duramed subsidiary have attained exclusive distribution of SAM Pro 2.0 in the United States for
no-fault insurance. Under its agreement with Sam International and ZetrOZ Systems, Canbiola is committed to purchasing
100 units per month starting in January and ramping to 150 units per month by June, for a total of 1,650 units for 2019.
Canbiola's marketing strategy is to provide equipment and services to both medical offices as well as direct to
consumer. We are presently billing and collecting from the insurance companies at $58 per day per unit. Given
discussions with the medical community, including doctors and patients, the Company believes the patient will use the
Sam unit and pads for an average of 35 days per cycle and that each unit will cycle an estimated 7 times per year. Thus,
each unit potentially provides $14,210 in gross rental revenue per year.
Canbiola Chief Executive Officer Marco Alfonsi, commented, "We are very excited in achieving this milestone of launching
a revolutionary solution that addresses a much-needed void in the market to accelerate tissue healing and chronic pain
reduction. Our proprietary CBD gels coupled with the unique SAM delivery system, which we have exclusive U.S. rights
within no-fault insurance to, will potentially drive our acceleration of both revenues and gross margins over the next
twelve months."
About Canbiola, Inc.
Canbiola, Inc. (OTCQB: CANB) is a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products
such as oils, creams, moisturizers, chews, vapes, isolate, gel caps, concentrate and water. Canbiola has developed its
own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical
cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a
limited number of states, but pure CBD products are legal in all 50 states. For more information about Canbiola, Inc.,
please visit: https://canbiola.com
ends